Lehdistötiedote31.3.2026 klo 6.00Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors
Lehdistötiedote2.3.2026 klo 6.00Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting
Lehdistötiedote25.2.2026 klo 15.45The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines
Lehdistötiedote12.2.2026 klo 16.45Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines
Lehdistötiedote6.2.2026 klo 7.00Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover
Pörssitiedote22.12.2025 klo 7.00Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover
Pörssitiedote21.11.2025 klo 7.00Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851
Lehdistötiedote9.10.2025 klo 7.00Novakand Pharma provides an update on the ongoing reverse take over process
Pörssitiedote23.9.2025 klo 13.00Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board
Pörssitiedote18.9.2025 klo 16.00Kancera initiates process to seek stakeholders for a reverse take over
Pörssitiedote28.8.2025 klo 6.00Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851
Lehdistötiedote16.6.2025 klo 6.30Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145
Pörssitiedote23.5.2025 klo 6.00Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851
Lehdistötiedote20.5.2025 klo 6.30Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program